+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the management of gastrointestinal stromal tumors

Recent advances in the management of gastrointestinal stromal tumors

Current Oncology Reports 5(4): 288-294

Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described. The KIT gene is commonly mutated, causing constitutive activation of the protein and aberrant growth. Recently, tumors with platelet-derived growth factor receptor (PDGFR)-a mutations have been described in GISTs with wild-type KIT. Factors that predict for an unfavorable outcome are being recognized. A specific molecularly targeted drug, imatinib mesylate, has altered the treatment of this disease. The results of phase I, II, and III clinical trials have consistently demonstrated activity of this agent and elucidated the patient and tumor characteristics associated with response to imatinib. The current challenge in caring for these patients is to identify the appropriate clinical setting for treatment with imatinib and to define the approach to patients whose tumors are insensitive or refractory to imatinib.

(PDF emailed within 0-6 h: $19.90)

Accession: 060175454

Download citation: RISBibTeXText

PMID: 12781070

DOI: 10.1007/s11912-003-0068-9

Related references

Recent advances in the management of gastrointestinal stromal tumors. F1000 Medicine Reports 2: -, 2010

Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports 9(3): 165-169, 2007

Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology 6(3): 115-127, 2014

Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology 30(10): 1213-1220, 1999

Advances and Challenges on Management of Gastrointestinal Stromal Tumors. Frontiers in Oncology 8: 135-135, 2018

Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location. Intractable & Rare Diseases Research 2(1): 11-17, 2013

Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium. Clinical Advances in Hematology & Oncology 15 Suppl 4(4): 1-24, 2018

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007

Recent advances in managing gastrointestinal stromal tumor. F1000research 6: 1689-1689, 2017

Dedifferentiated gastrointestinal stromal tumor: Recent advances. Annals of Diagnostic Pathology 2019, 2019

Frontiers of Gastrointestinal Research, Vol 23 Endocrine tumors of the pancreas Recent advances in research and management. Mignon, M , Jensen, R T Frontiers of Gastrointestinal Research; Endocrine tumors of the pancreas: Recent advances in research and management xii+482p, 1995

Recent advances and novel agents for gastrointestinal stromal tumor GIST. Journal of Hematology & Oncology 5(1): 21, 2012

Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathology International 65(1): 9-18, 2015

Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Journal of Hematology & Oncology 5: 21-21, 2012

Advances in adjuvant therapy of gastrointestinal stromal tumors. Current Oncology Reports 14(4): 327-332, 2012